Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization

Clinical Therapeutics

Volumn 19, Issue 3, 1997, Pages 582-602

  Spearman, Marshall E ^a   Summers, Kent ^b   Moore, Virginia ^c   Jacqmin, Robert ^d   Smith, Gary ^e   Groshen, Susan ^f  

^a Prudential Hlthcare Pharm Services   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c North Texas Health Care Associates   (United States)

^d Physician Reliance Network   (United States)

^e LABORATORY CORPORATION OF AMERICA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cost effectiveness; HMG CoA reductase inhibitors; Hypercholesterolemia; Statins

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030762162     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80142-7     Document Type: Article

References (52)

1. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann Intern Med. 1971;74:1-12.
2. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,622 men. Lancet. 1986;2:933-939.
3. Rose G, Shipley M. Plasma cholesterol concentration and death from coronary disease: 10 year results of the Whitehall Study. BMJ. 1986;293:306-307.
4. Goldbourt U, Yaari S. Cholesterol and coronary heart disease mortality: A 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990;10:512-519.
5. Pekkanen J, Nissinen A, Punsar S, Karvonen MJ. Short- and long-term association of serum cholesterol with mortality: The 25-year follow-up of the Finnish cohorts of the seven countries study. Am J Epidemiol. 1992;135:1251-1258.
6. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA. 1990; 263:393-396.
7. Aronow WS, Ahn C. Correlation of serum lipids with the presence or absence of coronary artery disease in 1793 men and women aged ≥ 62 years. Am J Cardiol. 1994;73:702-703.
8. Isles CG, Hole DJ, Gillis CR, et al. Plasma cholesterol, coronary heart disease, and cancer in the Renfrow and Paisley survey. BMJ. 1989;298:920-924.
9. Neaton JD, Kuller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentrations, and diastolic blood pressure among black and white males followed for five years. Am Heart J. 1984;108:759-769.
10. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;253:2080-2086.
11. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988; 223:405-418.
12. ATP II Panel. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269: 3015-3023.
13. Schuler G, Hanbredt R, Schlierf G, et al. Regular physical exercise and low-fat diet: Effects on progression of coronary artery disease. Circulation. 1992;86:1-11.
14. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: Results of the NHLBI type II coronary intervention study. Circulation. 1984;69: 313-324.
15. Blankenhorn DH, Nessim SA, Johnson RD, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
16. Alderman EL, Haskell WL, Fair JM, et al. Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89: 975-990.
17. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
18. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG-CoA reductase inhibitors: A new therapeutic alternative. Drugs. 1988;36(Suppl 3):72-82.
19. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. NEJM. 1988;319:24-33.
20. Davidson MH. Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety. Am J Med. 1994;96 (Suppl 6A):6A-415-6A-445.
21. Bradford RH, Shear CL, Athanassios NC, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
22. Behounek BD, McGovern ME, Kessler-Taub KB, et al. Effects of pravastatin in patients with serum cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72:1031-1037.
23. Farmer JA, Washington LC, Jones PH, et al. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. Clin Ther. 1992;14:708-717.
24. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? NEJM. 1995;332:1125-1131.
25. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995;29:743-759.
26. Havel RJ, Rapaport E. Management of primary hyperlipidemia. NEJM. 1995; 332:1491-1498.
27. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs: Cost-effectiveness of pharmacological management. JAMA. 1990;264:3025-3033.
28. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
29. Hay JW, Wittels EH, Gotto AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991;67:789-792.
30. Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994;16:1052-1067.
31. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: Effect on serum lipids and costs. Am J Health Syst Pharm. 1995;52:1078-1082.
32. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994;73(Suppl):3D-11D.
33. Zar JH. Single factor analysis of variance by ranks. In: Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, Inc; 1974:139-142.
34. Zar JH. Confidence intervals for differences between means. In: Biostatistical Analysis. Englewood Cliffs, NJ: PrenticeHall, Inc; 1974:155-156.
35. Larson LN. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. New York: Harvey Whitney Books; 1994:35-49.
36. Drummond MF, Stoddart GL, Torrance GW. Critical assessment of economic evaluation. In: House J, ed. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 1994:26-27.
37. Task Force on Principles for Economic Analysis of Health Care Technology. Economic analysis of health care technology: A report of principles. Ann Intern Med. 1995;122:61-70.
38. Guyatt G, Drummond M, Feeny D, et al. Guidelines for the clinical and economic evaluation of health care technologies. Soc Sci Med. 1986;22:393-408.
39. Chrischilles EA. Cost-effectiveness analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. New York: Harvey Whitney Books; 1991:72-101.
40. Krischner CG, Burkett RC, Kotowicz GM, et al, eds. Physicians' Current Procedural Terminology (CPT 1995). Chicago, Ill: American Medical Association; 1994.
41. Medical Prevailing Healthcare Charges System. Washington, DC: Health Insurance Association of America; May 1995.
42. US Department of Labor. Vital Statistics, 1994. Washington, DC: Bureau of Labor Statistics; 1994.
43. Rovira J, Antonanzas F. Economic analysis of health technologies and programmes: A Spanish proposal for methodological standardization. PharmacoEconomics. 1995; 8:245-252.
44. Sacristan J, Simon JD, Navarro O, et al. Use of confidence intervals and sample size calculations in health economic studies. Ann Pharmacother. 1995;29:719-724.
45. Epstein RS, Garrahan S, Nelsen L, et al. The cholesterol population model: US population requirements for treatment of hypercholesterolemia. Am J Managed Care. 1996;2:1362-1370.
46. Zovoral JH, Haggerty BJ, Winick AG, Bergmann SD. FLUENT Study Group. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 1995; 76(Suppl 2):37A-40A.
47. Baggio G, DeCandia O, Forte PL. Efficacy and safety of fluvastatin, a new HMG-CoA reductase inhibitor, in elderly hypercholesterolemic women. Drugs. 1994;47(Suppl):59-63.
48. Dallongevvile J, Fruchant J-C, Pfister P, Bard J-M, for the European Fluvastatin Study Group. Fluvastatin reduces levels of plasma apo B-containing particles and increases those of Lp(a)-1. Am J Med. 1994;96(Suppl):325-365.
49. McPherson R, Bedford J, Connally P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther. 1992;14: 276-291.
50. Stalenhoef AF, Lansberg PJ, Kroon AA, et al. Treatment of primary hypercholesterolemia: Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: A double-blind comparative study. J Intern Med. 1993;234:77-82.
51. Tronulefro J, Guinaracas AC, Kettoer H, et al. Dose-response of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol. 1994;24:941-949.
52. Salonen R, Kristijna N, Porkkala E, et al. Kupio Atherosclerosis Prevention Study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995; 92:1758-1764.